*NEWS: Novartis Confirmation of Alcon Spinoff Happens to Coincide with OCTANe’s Ophthalmology Technology Summit. Alcon Says Will Keep Manufacturing and BD&L in OC.
OCTANe’s annual 2018 Ophthalmology Technology Summit on June 29 coincided with the national news that Novartis will definitely spin off Alcon – with a presence in Lake Forest - to shareholders and buy back up to $5 billion in stock,
An OC-based fund dedicated to ophthalmology ventures has been a success for investors and a sequel fund will be launched. That’s the news relayed Friday by Visionary Ventures Fund LP Managing Partner Jeffry Weinhuff. He announced the news at OCTANe’s annual
OCTANe TIF panel. (L-R: David Meltzer, CEO, Sports 1 Marketing; Leonard Lanzi, executive director, LAVA; Mike Krenn, president, SDVG; Bill Carpou, CEO, OCTANe) On the heels of a recent announcement that OCTANe has joined forces with Los Angeles Venture
Accelerating growth throughout SoCal is a main mission of OCTANe, a technology and life sciences accelerator, in Aliso Viejo. To that end, it used its annual Technology Innovation Forum (TIF) on May 31-June 1 to formally announce a shift in
Bill Carpou, CEO, OCTANe OC’s startup ecosystem, Digital Coast, is young comparatively, but vibrant and growing. OC startups have been acquired by major tech companies, as was the case with Facebook’s $2 billion acquisition of VR hardware startup Occulus
Alan Benjamin, CEO, GigaIO OCTANe, the Aliso Viejo technology and life sciences accelerator, is working to prepare eight companies for its annual Technology Innovation Forum later this month. (see info on the event here). The focus of the conference will
Recorded Live at the Nasdaq Market Site in Times Square. SCN Corporate Connect's Jane King interviews CEO Bill Carpou of OCTANe about the latest with the company and its upcoming Technology Innovation Forum conference, focused on high-growth technology innovation and investment. https://www.youtube.com/watch?v=fbweNJnlH64&feature=youtu.be